支气管哮喘患者血清LXA4水平及凝血功能与肺功能及哮喘病程的相关性研究
|
摘要
目的评价支气管哮喘患者的血清LXA4水平及凝血功能与肺功能及哮喘病程间的相关性。方法选取2017年1～12月收治的的哮喘患者97例,根据病程长短分为A(<1年组)、B(1～9年组)、C(≥10年组)3组,比较3组患者的血清LXA4水平、凝血功能、肺功能,并分析血清LXA4水平及凝血功能与肺功能及哮喘病程间的关系。结果 C组LXA4水平显著高于B组和A组,随着病程增长,LXA4的水平显著增加,3组比较差异有统计学意义(P<0.05);3组间FIB、APTT、FEV1%比较差异有统计学意义(P<0.05),随着病程的增长,FIB、APTT、FEV1%均显著呈显著下降的趋势;3组间LXA4水平均随着FEV1%的降低而显著升高,LXA4与FEV 1%呈负相关性(r=-0.377,P<0.05),FIB及APTT随着FEV1%的降低而显著降低,FIB及APTT与FEV 1%呈正相关性(r FIB=0.025,P<0.05;rAPTT=0.257,P<0.05);LXA4的水平随着病程的延长显著增加(r=7.722,P<0.05),FIB及APTT随着病程呈显著下降的趋势(r FIB=-0.074,P<0.05;rAPTT=-0.747,P<0.05)。结论随着病程增长,患者血清LXA4及凝血功能存在着明显变化,在肺功能检测的基础上联合检测其水平有助于对支气管哮喘患者的诊断、治疗和预后。
Objective To evaluate the correlation of serum LXA4 levels and coagulation function to pulmonary function and duration of asthma in patients with bronchial asthma.Methods Ninety-seven patients with asthma who were admitted and treated in our hospital from January 2017 to December 2017 were divided into three groups according to the duration of disease: group A(<1-year group), group B(1～9 year group), and group C(≥10 years or more group). Serum LXA4 levels, coagulation function, and pulmonary function were compared in the three groups, and the relationship of serum LXA4 levels and coagulation function to pulmonary function and duration of asthma was analyzed.Results The levels of LXA4 in group C were significantly higher than those in group B and group A. The levels of LXA4 were increased significantly with the increase of disease duration, there were statistically significant differences among the three groups(P<0.05). There were significant differences in FIB, APTT and FEV1% among the three groups(P<0.05). FIB, APTT and FEV1% showed a significant decrease with the increase of disease duration. The LXA4 levels in the three groups were increased significantly with the decrease of FEV1%, and LXA4 was negatively correlated with FEV 1%(r=-0.377,P<0.05). In contrast, FIB and APTT were reduced significantly with the decrease of FEV1%, moreover, FIB and APTT were positively correlated with FEV 1%(r FIB =0.025,P<0.05; rAPTT =0.257,P<0.05). The levels of LXA4 were increased significantly with the increase of disease duration(r=7.722, P<0.05), whereas FIB and APTT showed a significant downward trend(r FIB=-0.074,P<0.05; rAPTT=-0.747,P<0.05).Conclusion With the increase of disease duration, there is a significant change in serum LXA4 and coagulation function. Combined detection of serum LXA4 and coagulation function on the basis of pulmonary function test is helpful for diagnosis, treatment and prognosis of patients with bronchial asthma.
Objective To evaluate the correlation of serum LXA4 levels and coagulation function to pulmonary function and duration of asthma in patients with bronchial asthma.Methods Ninety-seven patients with asthma who were admitted and treated in our hospital from January 2017 to December 2017 were divided into three groups according to the duration of disease: group A(<1-year group), group B(1～9 year group), and group C(≥10 years or more group). Serum LXA4 levels, coagulation function, and pulmonary function were compared in the three groups, and the relationship of serum LXA4 levels and coagulation function to pulmonary function and duration of asthma was analyzed.Results The levels of LXA4 in group C were significantly higher than those in group B and group A. The levels of LXA4 were increased significantly with the increase of disease duration, there were statistically significant differences among the three groups(P<0.05). There were significant differences in FIB, APTT and FEV1% among the three groups(P<0.05). FIB, APTT and FEV1% showed a significant decrease with the increase of disease duration. The LXA4 levels in the three groups were increased significantly with the decrease of FEV1%, and LXA4 was negatively correlated with FEV 1%(r=-0.377,P<0.05). In contrast, FIB and APTT were reduced significantly with the decrease of FEV1%, moreover, FIB and APTT were positively correlated with FEV 1%(r FIB =0.025,P<0.05; rAPTT =0.257,P<0.05). The levels of LXA4 were increased significantly with the increase of disease duration(r=7.722, P<0.05), whereas FIB and APTT showed a significant downward trend(r FIB=-0.074,P<0.05; rAPTT=-0.747,P<0.05).Conclusion With the increase of disease duration, there is a significant change in serum LXA4 and coagulation function. Combined detection of serum LXA4 and coagulation function on the basis of pulmonary function test is helpful for diagnosis, treatment and prognosis of patients with bronchial asthma.
引文
1 Sullivan PW,Ghushchyan VH,Slejko JF,et al.The burden of adult asthma in the United States:evidence from the Medical Expenditure Panel Survey.J Allerg Clin Immun,2011,127:1-3.
2 Zietkowski Z,Bodzenta-Lukaszyk A,Tomasiak MM,et al.Comparison of exhaled nitric oxide measurement with conveational tests in steroid-naive asthma patients.J Investing Allergol Clin Immunol,2006,16:239-246.
3 吴升华,何祚光.脂氧素研究进展.国际检验医学杂志,2003,24:255-257.
4 Dong F,Wang C,Duan J,et al.Puerarin attenuates ovalbumin-induced lung inflammation and hemostatic unbalance in rat asthma model.Evid Based Complement Alternat Med,2014,2014:726-740.
5 中华医学会呼吸病学分会哮喘学组,支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案).中华结核和呼吸杂志,2008,31:177-185.
6 Turner AM,Tamasi L,Schleich F,et al.Clinically relevant subgroups in COPD and asthma.Eur Respir Rev,2015,24:283-298.
7 Chung KF,Wenzel SE,Brozek JL,et al.International ERS/ATS guidelines on definition,evaluation and treatment of severe asthma.Europ Respir J,2014,44:267-267.
8 张蓉,章怡苇,汪燕.脂氧素在急性肺损伤中作用及机制的研究进展.上海交通大学学报(医学版),2016,36:926-929.
9 殷佩玲,吴升华.脂氧素与哮喘.国际呼吸杂志,2006,26:595-599.
10 Cindy B,Manuela C,Stefanie D,et al.Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma.Science Translational Medicine,2013,5:1447-1452.
11 赵丹,哈依努尔,克丽别娜·吐尔逊.支气管哮喘患者凝血功能状态的临床分析.临床肺科杂志,2013,18:1701-1702.
12 Hernandez JM,Janssen LJ.Revisiting the usefulness of thromboxane-A2 modulation in the treatment of bronchoconstriction in asthma.Can J Physiol Pharmacol,2015,93:111-117.
13 Matsumoto T,Matsushima Y,Toda M,et al.Activated protein C modulates the proinflammatory activity of dendritic cells.J Asthma Allergy,2015,8:29-37.
2 Zietkowski Z,Bodzenta-Lukaszyk A,Tomasiak MM,et al.Comparison of exhaled nitric oxide measurement with conveational tests in steroid-naive asthma patients.J Investing Allergol Clin Immunol,2006,16:239-246.
3 吴升华,何祚光.脂氧素研究进展.国际检验医学杂志,2003,24:255-257.
4 Dong F,Wang C,Duan J,et al.Puerarin attenuates ovalbumin-induced lung inflammation and hemostatic unbalance in rat asthma model.Evid Based Complement Alternat Med,2014,2014:726-740.
5 中华医学会呼吸病学分会哮喘学组,支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案).中华结核和呼吸杂志,2008,31:177-185.
6 Turner AM,Tamasi L,Schleich F,et al.Clinically relevant subgroups in COPD and asthma.Eur Respir Rev,2015,24:283-298.
7 Chung KF,Wenzel SE,Brozek JL,et al.International ERS/ATS guidelines on definition,evaluation and treatment of severe asthma.Europ Respir J,2014,44:267-267.
8 张蓉,章怡苇,汪燕.脂氧素在急性肺损伤中作用及机制的研究进展.上海交通大学学报(医学版),2016,36:926-929.
9 殷佩玲,吴升华.脂氧素与哮喘.国际呼吸杂志,2006,26:595-599.
10 Cindy B,Manuela C,Stefanie D,et al.Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma.Science Translational Medicine,2013,5:1447-1452.
11 赵丹,哈依努尔,克丽别娜·吐尔逊.支气管哮喘患者凝血功能状态的临床分析.临床肺科杂志,2013,18:1701-1702.
12 Hernandez JM,Janssen LJ.Revisiting the usefulness of thromboxane-A2 modulation in the treatment of bronchoconstriction in asthma.Can J Physiol Pharmacol,2015,93:111-117.
13 Matsumoto T,Matsushima Y,Toda M,et al.Activated protein C modulates the proinflammatory activity of dendritic cells.J Asthma Allergy,2015,8:29-37.